Ocular Therapeutix, Inc financial data

Symbol
OCUL on Nasdaq
Location
15 Crosby Drive, Bedford, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 962 % -30%
Quick Ratio 7.48 % -4.47%
Debt-to-equity 50.7 % +9.36%
Return On Equity -87.2 % -53.6%
Return On Assets -57.9 % -49.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 213M shares +35.5%
Common Stock, Shares, Outstanding 175M shares +11.7%
Entity Public Float 1.06B USD +162%
Common Stock, Value, Issued 18K USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 184M shares +10.1%
Weighted Average Number of Shares Outstanding, Diluted 184M shares +10.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 55.8M USD -9.21%
Research and Development Expense 187M USD +82.1%
Selling and Marketing Expense 51.8M USD +29.5%
General and Administrative Expense 61.3M USD +13.4%
Costs and Expenses 307M USD +51.3%
Operating Income (Loss) -251M USD -77.6%
Nonoperating Income (Expense) 1.16M USD -108%
Net Income (Loss) Attributable to Parent -250M USD -43.2%
Earnings Per Share, Basic -1 USD/shares -6.06%
Earnings Per Share, Diluted -1 USD/shares -28.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 345M USD -19.3%
Accounts Receivable, after Allowance for Credit Loss, Current 30.8M USD +1.76%
Inventory, Net 3.49M USD +45%
Assets, Current 387M USD -18.2%
Property, Plant and Equipment, Net 17M USD +68.7%
Operating Lease, Right-of-Use Asset 5.33M USD -6.32%
Assets 411M USD -16.2%
Accounts Payable, Current 6.26M USD +56.5%
Employee-related Liabilities, Current 13.1M USD +17.5%
Accrued Liabilities, Current 40.3M USD +32.3%
Contract with Customer, Liability, Current 64K USD -75.7%
Liabilities, Current 49.3M USD +35.6%
Contract with Customer, Liability, Noncurrent 14M USD 0%
Operating Lease, Liability, Noncurrent 3.63M USD -35.1%
Other Liabilities, Noncurrent 151K USD +29.1%
Liabilities 153M USD +10.3%
Retained Earnings (Accumulated Deficit) -1.09B USD -29.6%
Stockholders' Equity Attributable to Parent 258M USD -26.6%
Liabilities and Equity 411M USD -16.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -44.7M USD -31.8%
Net Cash Provided by (Used in) Financing Activities 4.18M USD -98.7%
Net Cash Provided by (Used in) Investing Activities -1.93M USD -658%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 175M shares +11.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -42.4M USD -115%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 346M USD -19.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.14M USD -83.5%
Deferred Tax Assets, Valuation Allowance 225M USD +22.6%
Deferred Tax Assets, Gross 229M USD +17.6%
Operating Lease, Liability 7.28M USD -14%
Payments to Acquire Property, Plant, and Equipment 1.93M USD +658%
Lessee, Operating Lease, Liability, to be Paid 8.74M USD -18.4%
Property, Plant and Equipment, Gross 33M USD +3.19%
Operating Lease, Liability, Current 2.76M USD +60.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.09M USD +15.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.72M USD +8.71%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.46M USD -35.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.18M USD -19.6%
Deferred Tax Assets, Operating Loss Carryforwards 135M USD +11.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 750K USD -64.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 981K USD +6.63%
Deferred Tax Assets, Net of Valuation Allowance 3.63M USD -66.5%
Share-based Payment Arrangement, Expense 39M USD +29%
Interest Expense 13.6M USD +91.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%